

Matthew J Koster

List of Publications by Citations

Source: <https://exaly.com/author-pdf/3782095/matthew-j-koster-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

66

papers

609

citations

13

h-index

23

g-index

72

ext. papers

924

ext. citations

4

avg, IF

4.47

L-index

#	Paper	IF	Citations
66	Predictors of relapse and treatment outcomes in biopsy-proven giant cell arteritis: a retrospective cohort study. <i>Rheumatology</i> , 2016 , 55, 347-56	3.9	85
65	Large-vessel giant cell arteritis: diagnosis, monitoring and management. <i>Rheumatology</i> , 2018 , 57, ii32-ii42	3.9	75
64	The Mayo Clinic Histiocytosis Working Group Consensus Statement for the Diagnosis and Evaluation of Adult Patients With Histiocytic Neoplasms: Erdheim-Chester Disease, Langerhans Cell Histiocytosis, and Rosai-Dorfman Disease. <i>Mayo Clinic Proceedings</i> , 2019 , 94, 2054-2071	6.4	60
63	Recent advances in the clinical management of giant cell arteritis and Takayasu arteritis. <i>Current Opinion in Rheumatology</i> , 2016 , 28, 211-7	5.3	46
62	Coronary artery disease in giant cell arteritis: a systematic review and meta-analysis. <i>Seminars in Arthritis and Rheumatism</i> , 2015 , 44, 586-591	5.3	30
61	Giant cell arteritis: pathogenic mechanisms and new potential therapeutic targets. <i>BMC Rheumatology</i> , 2017 , 1, 2	2.9	24
60	Cerebrovascular accident in patients with giant cell arteritis: A systematic review and meta-analysis of cohort studies. <i>Seminars in Arthritis and Rheumatism</i> , 2016 , 46, 361-366	5.3	24
59	Clinical Spectrum of Medium-Sized Vessel Vasculitis. <i>Arthritis Care and Research</i> , 2017 , 69, 884-891	4.7	22
58	Efficacy of biological agents in the treatment of Erdheim-Chester disease. <i>British Journal of Haematology</i> , 2018 , 183, 520-524	4.5	20
57	Assessment of the frequency of cardiovascular risk factors in patients with Takayasu arteritis. <i>Rheumatology</i> , 2017 , 56, 1939-1944	3.9	19
56	Efficacy of Methotrexate in Real-world Management of Giant Cell Arteritis: A Case-control Study. <i>Journal of Rheumatology</i> , 2019 , 46, 501-508	4.1	16
55	Classification of large vessel vasculitis: Can we separate giant cell arteritis from Takayasu arteritis?. <i>Presse Medicale</i> , 2017 , 46, e205-e213	2.2	14
54	Risk of venous thromboembolism among patients with vasculitis: a systematic review and meta-analysis. <i>Clinical Rheumatology</i> , 2016 , 35, 2741-2747	3.9	13
53	Venous Thromboembolism and Cerebrovascular Events in Patients with Giant Cell Arteritis: A Population-Based Retrospective Cohort Study. <i>PLoS ONE</i> , 2016 , 11, e0149579	3.7	12
52	Indirect comparisons of the efficacy of biological agents in patients with active ankylosing spondylitis: a systematic review and meta-analysis. <i>Clinical Rheumatology</i> , 2017 , 36, 1569-1577	3.9	10
51	Polymyalgia rheumatica and risk of coronary artery disease: a systematic review and meta-analysis of observational studies. <i>Rheumatology International</i> , 2017 , 37, 143-149	3.6	10
50	Clinical Characteristics of Biopsy-Proven IgA Vasculitis in Children and Adults: A Retrospective Cohort Study. <i>Mayo Clinic Proceedings</i> , 2019 , 94, 1769-1780	6.4	9

49	Disease progression of Takayasu arteritis in two patients treated with tocilizumab. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, e21	2.4	8
48	Rituximab Therapy for Systemic Rheumatoid Vasculitis: Indications, Outcomes, and Adverse Events. <i>Journal of Rheumatology</i> , 2020 , 47, 518-523	4.1	8
47	Cranial Base Manifestations of Granulomatosis with Polyangiitis. <i>Otolaryngology - Head and Neck Surgery</i> , 2020 , 162, 666-673	5.5	7
46	Inpatient epidemiology and economic burden of granulomatosis with polyangiitis: a 10-year study of the national inpatient sample. <i>Rheumatology</i> , 2020 , 59, 3685-3689	3.9	7
45	Smoking as a risk factor for giant cell arteritis: A systematic review and meta-analysis. <i>Seminars in Arthritis and Rheumatism</i> , 2018 , 48, 529-537	5.3	7
44	Single-agent cladribine as an effective front-line therapy for adults with Langerhans cell histiocytosis. <i>American Journal of Hematology</i> , 2021 , 96, E146-E150	7.1	7
43	Clinical Heterogeneity of the VEXAS Syndrome: A Case Series. <i>Mayo Clinic Proceedings</i> , 2021 , 96, 2653-2659	6.9	7
42	Vasculitis of the mesenteric circulation. <i>Baillieres Best Practice and Research in Clinical Gastroenterology</i> , 2017 , 31, 85-96	2.5	6
41	Morbidity and Mortality of Large-Vessel Vasculitides. <i>Current Rheumatology Reports</i> , 2020 , 22, 86	4.9	6
40	Baricitinib for relapsing giant cell arteritis: a prospective open-label 52-week pilot study.. <i>Annals of the Rheumatic Diseases</i> , 2022 ,	2.4	5
39	Update on the Epidemiology and Treatment of Giant Cell Arteritis. <i>Current Treatment Options in Rheumatology</i> , 2016 , 2, 138-152	1.3	4
38	Clinical Efficacy of JAK Inhibitors in Patients with Vexas Syndrome: A Multicenter Retrospective Study. <i>Blood</i> , 2021 , 138, 2608-2608	2.2	4
37	Healthcare Use and Direct Cost of Giant Cell Arteritis: A Population-based Study. <i>Journal of Rheumatology</i> , 2017 , 44, 1044-1050	4.1	4
36	Acute digital ischemia: A rare presentation of antisynthetase syndrome. <i>European Journal of Rheumatology</i> , 2017 , 4, 63-65	1.7	4
35	Clinical and Radiographic Features of Giant Cell Arteritis With Intracranial Involvement. <i>ACR Open Rheumatology</i> , 2020 , 2, 471-477	3.5	4
34	Giant cell arteritis and its mimics: A comparison of three patient cohorts. <i>Seminars in Arthritis and Rheumatism</i> , 2020 , 50, 923-929	5.3	3
33	VEXAS within the spectrum of rheumatologic disease. <i>Seminars in Hematology</i> , 2021 , 58, 218-225	4	3
32	Recent advances in understanding and treating vasculitis. <i>F1000Research</i> , 2016 , 5,	3.6	3

31	Prevalence of Takayasu Arteritis: A Population-based Study. <i>Journal of Rheumatology</i> , 2021 , 48, 952	4.1	3
30	Cardiopulmonary involvement in Takayasu's arteritis. <i>Clinical and Experimental Rheumatology</i> , 2018 , 36 Suppl 111, 46-50	2.2	3
29	Inpatient burden and association with comorbidities of polyarteritis nodosa: National Inpatient Sample 2014. <i>Seminars in Arthritis and Rheumatism</i> , 2020 , 50, 66-70	5.3	2
28	Pleuritis and Pericarditis in Antineutrophil Cytoplasmic Autoantibody-Associated Vasculitis. <i>Chest</i> , 2021 , 160, 572-581	5.3	2
27	Langerhans cell histiocytosis with lung involvement in isolation and multisystem disease: Staging, natural history, and comparative survival. <i>American Journal of Hematology</i> , 2021 , 96, 1604-1610	7.1	2
26	Occurrence and aetiology of gastrointestinal perforation in patients with vasculitis. <i>Clinical and Experimental Rheumatology</i> , 2019 , 37 Suppl 117, 32-39	2.2	2
25	Synovial infiltration in human T lymphotropic virus type I-associated adult T cell leukemia/lymphoma. <i>Arthritis and Rheumatology</i> , 2015 , 67, 945	9.5	1
24	Diffuse large B cell lymphoma involving Meckel's cave masquerading as biopsy-negative giant cell arteritis: a case report. <i>Journal of Medical Case Reports</i> , 2020 , 14, 57	1.2	1
23	Efficacy of Cobimetinib in Rosai-Dorfman Disease. <i>Blood</i> , 2021 , 138, 1506-1506	2.2	1
22	Application of the 3SmRNA-Seq using unique molecular identifiers in highly degraded RNA derived from formalin-fixed, paraffin-embedded tissue. <i>BMC Genomics</i> , 2021 , 22, 759	4.5	1
21	Low-dose vemurafenib monotherapy in -mutated Erdheim-Chester disease. <i>Leukemia and Lymphoma</i> , 2020 , 61, 2733-2737	1.9	1
20	My Treatment Approach to Giant Cell Arteritis. <i>Mayo Clinic Proceedings</i> , 2021 , 96, 1530-1545	6.4	1
19	Giant cell arteritis associated with inflammatory bowel disease: a case-series and review of the literature. <i>Rheumatology International</i> , 2021 , 41, 487-492	3.6	1
18	Population-based Rate and Patterns of Diplopia in Giant Cell Arteritis.. <i>Neuro-Ophthalmology</i> , 2022 , 46, 75-79	0.9	1
17	Comparison of biopsy-proven giant cell arteritis in North America and Southern Europe: a population-based study. <i>Clinical and Experimental Rheumatology</i> , 2020 , 38 Suppl 124, 79-83	2.2	1
16	Exposure to TNF inhibitors is rare at MOGAD presentation. <i>Journal of the Neurological Sciences</i> , 2021 , 120044	3.2	0
15	Incidence, survival, and diagnostic trends in GCA across seven decades in a North American population-based cohort. <i>Seminars in Arthritis and Rheumatism</i> , 2021 , 51, 1193-1199	5.3	0
14	Comment on: Anti-tumour necrosis factor treatment for the prevention of ischaemic events in patients with deficiency of adenosine deaminase 2 (DADA2). <i>Rheumatology</i> , 2021 , 60, e218-e219	3.9	0

13	Vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome: a presentation of two cases with dermatologic findings.. <i>International Journal of Dermatology</i> , 2022 ,	1.7	0
12	In Reply, IgA Vasculitis (Henoch-Schönlein Purpura) in Argentina: Comparison Between Pediatric and Adult Population. <i>Mayo Clinic Proceedings</i> , 2020 , 95, 424	6.4	
11	In Reply-Giant Cell Arteritis: The Place of F-FDG PET/CT and Serum Haptoglobin Level.. <i>Mayo Clinic Proceedings</i> , 2022 , 97, 190	6.4	
10	A call for uniformity in reporting patient level details during description of ophthalmologic major relapse among giant cell arteritis studies. A comment on article by Aussedat M et al. "Epidemiology of major relapse in giant cell arteritis: A study-level meta-analysis".. <i>Autoimmunity Reviews</i> , 2022 , 21, 103062	13.6	
9	Classical and Non-Classical Phenotypes of Erdheim-Chester Disease: Correlating Clinical, Radiographic, and Genotypic Findings. <i>Blood</i> , 2021 , 138, 2566-2566	2.2	
8	Histopathologic Characterization of Vexas Syndrome. <i>Blood</i> , 2021 , 138, 4656-4656	2.2	
7	Tumor Mutational Burden and Other Immunotherapy Markers in Histiocytic Neoplasms Using Next Generation Sequencing. <i>Blood</i> , 2018 , 132, 1112-1112	2.2	
6	BRAFV600E frequency and impact on outcomes in adults with langerhans cell histiocytosis.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 7050-7050	2.2	
5	F-fluorodeoxyglucose positron emission tomography/computed tomography of giant cell arteritis with lower extremity involvement in association with polymyalgia rheumatica. <i>World Journal of Nuclear Medicine</i> , 2021 , 20, 90-92	0.6	
4	Development of biopsy-proven giant cell arteritis in a patient with dermatomyositis on methotrexate: comment on the article by Monti et al. <i>Clinical and Experimental Rheumatology</i> , 2020 , 38 Suppl 124, 239-240	2.2	
3	Comment on: Development of intracranial vasculitis in giant cell arteritis during tocilizumab treatment by Naderi. <i>Clinical and Experimental Rheumatology</i> , 2021 , 39 Suppl 129, 198	2.2	
2	Comment on: Development of intracranial vasculitis in giant cell arteritis during tocilizumab treatment by Naderi. <i>Clinical and Experimental Rheumatology</i> , 2021 , 39, 198-198	2.2	
1	Clinical features and outcomes of non-pulmonary unifocal adult Langerhans cell histiocytosis. <i>Blood Cancer Journal</i> , 2022 , 12,	7	